Intravenous Tirofiban After Tenecteplase in Acute Ischemic Stroke
JAMA · 09.06.2026 · 335 (22) · 1949
DOI: 10.1001/jama.2026.5245 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift JAMA, erschienen am 09.06.2026. Verfasst von INSTANT Trial Authors for the INSTANT Investigators und 59 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, The Affiliated Ganzhou Hospital of Nanchang University (Ganzhou People's Hospital), Ganzhou, China. Hauptthemen laut MEDLINE: Fibrinolytic Agents, Ischemic Stroke, Platelet Aggregation Inhibitors, Tenecteplase. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Themen: Schlaganfall
Abstract (Originalsprache)
Importance Although recent trials have shown benefit with early tirofiban after thrombolysis, its efficacy remains uncertain in patients with acute ischemic stroke who do not have a large or medium vessel occlusion or a cardioembolic source and who show an inadequate clinical response to intravenous tenecteplase.
Objective
To assess the efficacy and safety of intravenous tirofiban administered after an inadequate response to intravenous tenecteplase in this specific patient population. Design, Setting, and Participants Investigator-initiated, randomized, double-blind, placebo-controlled trial conducted at 37 hospitals in China, enrolling 359 patients with acute ischemic stroke, without large or medium vessel occlusion or cardioembolic etiology, and with an insufficient clinical response to intravenous tenecteplase (defined as no significant change from baseline, neurological deterioration, or neurological fluctuation based on serial assessment of the National Institutes of Health Stroke Scale score within 4-24 hours after infusion). Recruitment took place between April 24, 2024, and July 16, 2025, with final follow-up on October 11, 2025.
Interventions
Intravenous tirofiban (n = 177), administered as a 0.3-μg/kg/min bolus over 30 minutes, followed by a continuous infusion of 0.075 μg/kg/min for up to 47.5 hours, or matching placebo (n = 182), initiated within 4 to 24 hours after intravenous tenecteplase. Oral antiplatelet therapy (aspirin and/or clopidogrel) was started 24 hours after thrombolysis in the placebo group and 44 hours after thrombolysis in the tirofiban group and continued in all patients through 90-day follow-up. Main Outcomes and Measures The primary outcome was an excellent outcome (defined as a score of 0 or 1 on the modified Rankin Scale; range, 0-6, with higher scores indicating more severe disability) at 90 days. Safety outcomes included incidence of symptomatic intracranial hemorrhage within 48 hours and 90-day mortality.
Results
Among 359 patients randomized (mean age, 66 years; 141 females [39.3%]), 358 (99.7%) completed the trial. An excellent outcome at 90 days was observed in 113 patients (63.8%) in the tirofiban group and in 95 patients (52.2%) in the placebo group (risk ratio, 1.22; 95% CI, 1.02-1.46; P = .03). Symptomatic intracranial hemorrhage within 48 hours occurred in 1 patient (0.9%) in the tirofiban group and no patients in the placebo group; 90-day mortality was 0.6% and 1.6%, respectively. Conclusions and Relevance Among patients with acute ischemic stroke without large or medium vessel occlusion or a cardioembolic source who had an inadequate clinical response to intravenous tenecteplase, adjunctive intravenous tirofiban increased the likelihood of an excellent outcome at 90 days. Trial Registration ClinicalTrials.gov Identifier: NCT05604638
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Neurology, The Affiliated Ganzhou Hospital of Nanchang University (Ganzhou People's Hospital), Ganzhou, China.
- Ganzhou Hospital-Nanfang Hospital, Southern Medical University (Ganzhou People's Hospital), Ganzhou, China.
- Department of Neurology, Mingguang People's Hospital, Chuzhou, China.
- Department of Emergency, Xiangtan Central Hospital (The Affiliated Hospital of Hunan University), Xiangtan, China.
- Department of Neurology, The Second Affiliated Hospital of Guangxi Medical University, Nanning, China.
- Department of Neurology, Zhongmeng Hospital of Hexigten Banner, Chifeng, China.
Zitieren
APA
INSTANT Trial Authors for the INSTANT Investigators, Liu, X., Zhang, F., Zhang, C., Li, Z., Yuan, G., Kong, D., Xie, S., Zhou, M., Ye, J., Lai, Z., Li, D., Xu, H., Chen, L., Cheng, F., Shi, Y., Chen, B., Hu, W., Liu, H., …, & Nguyen, T. N. (2026). Intravenous Tirofiban After Tenecteplase in Acute Ischemic Stroke. JAMA, 335(22), 1949. https://doi.org/10.1001/jama.2026.5245
Vancouver
INSTANT Trial Authors for the INSTANT Investigators, Liu X, Zhang F, Zhang C, Li Z, Yuan G, et al. Intravenous Tirofiban After Tenecteplase in Acute Ischemic Stroke. JAMA. 2026;335(22):1949. doi:10.1001/jama.2026.5245
BibTeX
@article{INSTANTTrialAuthorsfortheINSTANTInvestigators2026,
author = {INSTANT Trial Authors for the INSTANT Investigators, INSTANT Trial Authors for the INSTANT Investigators and Liu, Xianghong and Zhang, Fan and Zhang, Cong and Li, Zongliang and Yuan, Guangxiong and Kong, Deyan and Xie, Shuhua and Zhou, Min and Ye, Jinchun and Lai, Zhaohui and Li, Dan and Xu, Hailong and Chen, Lei and Cheng, Fangqun and Shi, Yan and Chen, Bin and Hu, Weihua and Liu, Huashi and Yin, Yi and Deng, Xinbo and Xie, Zhiyong and Li, Chunying and Shi, Junfeng and Mei, Donghuan and Liu, Bin and Wang, Bo and Zhou, Ruize and Liu, Jingjing and Shen, Limin and Hu, Hairong and Xiao, Genxiang and Guan, Xiaoyu and Yuan, Shanggui and Lv, Xunwei and Liang, Shuiping and Zeng, Xiang and Chen, Yi and Cao, Wenfeng and Zheng, Chong and Liu, Yuanlu and Li, Junda and Guan, Baozhu and Lai, Tianmin and Sun, Wei and Zeng, Hongliang and Zhang, Jian and Li, Shizhan and Sang, Hongfei and Tang, Yamei and Wang, Duolao and Lu, Mengjie and Kaesmacher, Johannes and Yogendrakumar, Vignan and Pan, Suyue and Nogueira, Raul G and Hong, Daojun and Goyal, Mayank and Thomalla, Götz and Nguyen, Thanh N},
title = {Intravenous Tirofiban After Tenecteplase in Acute Ischemic Stroke},
journal = {JAMA},
year = {2026},
volume = {335},
number = {22},
pages = {1949},
doi = {10.1001/jama.2026.5245}
}
EUVIMED